Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Drug Profile

Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Alternative Names: Cymerus™ MSC; CYP-001

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Cynata Therapeutics
  • Developer Cynata Therapeutics; Monash University
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma; Graft-versus-host disease

Most Recent Events

  • 02 Mar 2017 Cynata Therapeutics and Monash University agree to develop mesenchymal stem cell therapy for Asthma
  • 17 Oct 2016 Preclinical trials in Asthma in Australia (IV)
  • 21 Sep 2016 The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves CTA for CYP 001 in Graft-versus-host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top